

Investigating Antivenom Function and Cross-Reactivity – a Study of Antibodies and Their Targets

Engmark, Mikael; De Masi, Federico; Andersen, Mikael Rørdam; Laustsen, Andreas Hougaard; Gutiérrez, José María; Lomonte, Bruno; Lund, Ole

Publication date:
2015

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Engmark, M., De Masi, F., Andersen, M. R., Laustsen, A. H., Gutiérrez, J. M., Lomonte, B., & Lund, O. (2015). Investigating Antivenom Function and Cross-Reactivity – a Study of Antibodies and Their Targets. Poster session presented at 12th Protein.DTU Workshop, Kgs. Lyngby , Denmark.

DTU Library

Technical Information Center of Denmark

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Investigating Antivenom Function and Cross-Reactivity – a Study of Antibodies and Their Targets

Mikael Engmark¹, Federico De Masi¹, Mikael Rørdam Andersen¹, Andreas Laustsen²,
José María Gutiérrez³, Bruno Lomonte³, and Ole Lund¹

¹Department of Systems Biology, Technical University of Denmark, ²Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, ³Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica

Snake Antivenom: an Essential Medicine – and a Black Box

Venomous snakebites are regarded as one of the World's most neglected tropical diseases/conditions with up to 2.5 million victims every year¹. The best-practice treatment is antivenom derived from the blood of large mammals (typically horses or sheep) immunized with venom of one or more snake species. The active toxin-neutralizing components in antivenom are complex mixtures of antibodies (or fragments hereof)². The individual antibodies are adapted by the immune system of the production animal to bind specific to parts of each toxin used in the immunization procedure. In many cases antivenom is also able to neutralize some – or even all – toxic effects of snakebites from related snake species³.

Proteomics-based studies aiming at quantifying the extent of such cross-protection of antivenoms against venoms from related snake species are referred to as antivenomics. The current state-of-the-art antivenomics protocol involves affinity chromatography of venoms with immobilized antibodies⁴. Although proven effective in clinical applications antivenomics fail to explain how this cross-reactivity is working at the molecular level and must be performed for one snake venom-antivenom pair at a time.

Knowledge of interactions between the immunoreactive parts (referred to as epitopes) of a toxin or macromolecule in general and the corresponding antibodies is a prerequisite to understand and predict neutralization potential of a given antivenom against any fully characterized snake venom. Although antivenom to snakebites is a more than 120 years old invention¹, only little is known about the neutralizing antibodies or their epitopes⁵.

Ideas and Perspectives

- Identify linear peptides from snake toxins that can bind antibodies in antivenom using custom designed high-density peptide microarray technology⁶. See figure 1
- The microarrays in this study have been designed to contain five technical replicates of 93'261 15-mer peptides derived 966 toxins from pit viper snake species (sub-family Viperidae).
- Localize epitopes in peptide hits
- Characterizing important antibody-toxin interactions based on allowed variation of epitope
- Predict cross-reactivity of antivenoms on a protein family level and thereby expand the clinical applications of existing antivenoms to other snake species or suggest changes in immunization mixture to improve the medicine
- Learning from nature's preferences for specific epitopes, it will be possible to estimate the number of antibodies needed to neutralize the critical toxins for any given snake species
- In the long run this may result in recombinant immunization mixtures and even lead to the first fully recombinant antivenom




Figure 1 – Schematic overview of principle in peptide microarray experiments

Result example – Venom Metalloproteinase P-I subfamily





Figure 2 – Signal plots for two snake venom metalloproteinases (SVMP) belonging to the P-I sub-family. Peaks in the signal plots result from binding events between consecutive peptides from the protein sequence of toxins and antibodies in ICP anti-Bothrops antivenom. *Bothrops asper* venom was used in the immunization procedure and the SVMP in the upper plot is known to represent approx. 30 % of the total protein composition in venom from adult specimens⁷. The SVMP from *Crotalus atrox* displayed the lower plot is not present in the immunization mixture but shares 60 % of the amino acids with the *B. asper* SVMP. The lower plot strongly indicates a cross-neutralization potential of the ICP antivenom.

P83512			Q90392		
#	Sequence	Signal	#	Sequence	Signal
7	RYIELAVVADHGIFT	0	7	RYIELVVVADHRVFM	0
8	YIELAVVADHGIFPK	207	8	YIELVVVADHRVFMK	120
9	IELAVVADHGIFPKY	225	9	IELVVVADHRVFMKY	138
10	ELAVVADHGIFPKYN	225	10	ELVVVADHRVFMKYN	201
11	LAVVADHGIFPKYNS	255	11	LVVVADHRVFMKYN	201
12	AVVADHGIFPKYNSN	255	12	VVVADHRVFMKYN	156
13	VVADHGIFPKYNSNL	255	13	VVADHRVFMKYN	156
14	VADHGIFPKYNSNLN	156	14	VADHRVFMKYN	51
15	ADHGIFPKYNSNLNT	105	15	ADHRVFMKYN	45
16	DHGIFPKYNSNLNTI	12	16	DHRVFMKYN	0

Figure 3 – Alignment of peptide 7 to 16 of the SVMPs from the signal plots in figure 2 including the running median signal score calculated as median of signals from peptide and the nearest neighbors on each side. The binding core is highlighted with red squares.

Figure 4 – Crystal structure of *B. asper* SVMP-PI (PDB entry 2W15). The α -helix highlighted in red correspond to the binding core of one or more antibody from the ICP antivenom



References

- [1] Williams, D. J. et al. Ending the drought: New strategies for improving the flow of affordable, effective antivenoms in Asia and Africa. *J. Proteomics* 74, 1735–1767 (2011).
- [2] Gutiérrez, J. M. et al. Snakebite envenoming from a global perspective: Towards an integrated approach. *Toxicon* 56, 1223–1235 (2010).
- [3] Calvete, J. J. et al. Antivenomic assessment of the immunological reactivity of EchiTAB-Plus-ICP, an antivenom for the treatment of snakebite envenoming in sub-Saharan Africa. *Am. J. Trop. Med. Hyg.* 82, 1194–1201 (2010).
- [4] Calvete, J. J. Next-generation snake venomomics: protein-locus resolution through venom proteome decomplexation. *Expert Rev. Proteomics* 11, 315–29 (2014).
- [5] Lomonte, B. Identification of linear B-cell epitopes on myotoxin II, a Lys49 phospholipase A₂ homologue from *Bothrops asper* snake venom. *Toxicon* 60, 782–90 (2012).
- [6] Buus, S. et al. High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays. *Mol. Cell. Proteomics* 11, 1790–800 (2012).
- [7] Alape-Girón, A. et al. Snake Venomomics of the Lancehead Pitviper *Bothrops Asper*. Geographic, Individual, and Ontogenetic Variations. *J. Proteome Res.* 7, 3556–3571 (2008).

Contact information

miken@bio.dtu.dk / (+45) 4016 6101

Acknowledgement

Collaborators: Christian Skjoldt Hansen (DTU), Andreas Laustsen (KU), Claus Schafer (Schafer-N Aps), Jens Kringelum (Evaxion Aps & EIR Sciences Aps)
Financial support: The Novo Nordisk Foundation